Table 2 Counts and percentages of Medicaid recipients with OUD who received psychosocial services and/or pharmacotherapy
2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | |
|---|---|---|---|---|---|---|---|
Total study population (N) | 107,398 | 158,677 | 167,939 | 172,539 | 482,081 | 491,125 | 455,607 |
Opioid use disorder (N, %) | |||||||
OUD diagnosis | 3653 (3.4) | 5733 (3.6) | 6235 (3.7) | 6808 (4.0) | 13,418 (2.8) | 15,251 (3.1) | 15,021 (3.3) |
Psychosocial services (N, %) | |||||||
Residential and detoxification | 83 (2.3) | 221 (3.9) | 414 (6.6) | 675 (9.9) | 1787 (13.3) | 1844 (12.1) | 2078 (13.8) |
Opioid treatment program | 1651 (45.2) | 2555 (44.6) | 2747 (44.1) | 2786 (40.9) | 4394 (32.8) | 4694 (30.8) | 4683 (31.2) |
Primary care | 123 (3.4) | 81 (1.4) | 98 (1.6) | 125 (1.8) | 478 (3.6) | 594 (3.9) | 938 (6.2) |
Specialty outpatient | 930 (25.5) | 1460 (25.5) | 1620 (26.0) | 2106 (30.9) | 3974 (29.6) | 4898 (32.1) | 4882 (32.5) |
Any psychosocial services | 2386 (65.3) | 3682 (64.2) | 4106 (65.9) | 4714 (69.2) | 8781 (65.4) | 10,028 (65.8) | 10,193 (67.9) |
Pharmacotherapy (N, %) | |||||||
Buprenorphine | 206 (5.6) | 396 (6.9) | 511 (8.2) | 634 (9.3) | 1483 (11.1) | 2006 (13.2) | 2335 (15.5) |
Methadone | 1651 (45.2) | 2555 (44.6) | 2747 (44.1) | 2786 (40.9) | 4394 (32.8) | 4694 (30.8) | 4683 (31.2) |
Oral naltrexone | 4 (0.1) | 13 (0.2) | 25 (0.4) | 38 (0.6) | 83 (0.6) | 173 (1.1) | 304 (2.0) |
Naltrexone ext-release | 2 (0.1) | 1 (0.0) | 51 (0.8) | 134 (2.0) | 459 (3.4) | 711 (4.7) | 941 (6.3) |
Any pharmacotherapy | 1844 (50.5) | 2925 (51.0) | 3270 (52.5) | 3464 (50.9) | 6093 (45.4) | 7075 (46.4) | 7617 (50.7) |